We observed an initial blunted response at time points 10 ( BrAC Control = 0.037, BrAC GLP-1RA = 0.021, t(113) = 3.21, p = 0.014), 15 ( BrAC Control = 0.028, BrAC GLP-1RA = 0.013, t(113) = 2.98, p = 0.028) and 20 min (BrAC Control = 0.037, BrAC GLP-1RA = 0.017, t(113) = 3.87, p = 0.001) in the GLP-1RA group as compared to the control group
Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy, Popovic V, Simic M, Ilic V, Micic D, Damjanovic S, Djurovic M, Obradovic S, Dieguez C, Casanueva FF, Clinical Endocrinology (1998, Vol
Diagnosis data were not available for some private healthcare providers on national contracts and online doctors not funded by the region, or care given by publicly funded digital healthcare providers based in other Swedish regions
Epitalon Dosing Patterns Reported in Clinical and Research Literature Epitalon remains under research in various study settings, and there are currently no officially approved dosing guidelines
Potency: Roughly 10 times stronger at receptor binding compared to native IGF-1
